Breakthrough Gene-Editing Treatment Targets Permanent Heart Disease Prevention in Landmark Trial

Scientists have developed a groundbreaking gene-editing therapy that significantly reduces cholesterol levels with just one administration, potentially offering a permanent solution to prevent heart disease. This preliminary finding, presented at a major medical conference, could transform how cardiovascular disease—which claims nearly 800,000 American lives annually—is addressed. The treatment uses a viral vector to deliver a gene-editing tool to the liver, where it permanently disables the PCSK9 gene responsible for high cholesterol.

In a small trial involving 35 participants with genetically elevated LDL cholesterol or existing heart disease, a single infusion led to a 62% reduction in LDL levels. Researchers followed patients for up to 18 months, confirming sustained results in some cases. The study, published in The New England Journal of Medicine, marks an unusual move for the journal to release interim trial data. However, experts emphasize the need for rigorous safety evaluations, including long-term patient monitoring for 15 years as required by the FDA.

Cardiologist Dr. John Alexander, uninvolved in the study, called the approach a “game-changer.” Dr. Eric Rubin, the journal’s editor, noted that while the results are promising, more data is needed before the therapy can be considered safe and effective. Dr. J. Michael Gaziano of the Boston V.A. health system echoed this caution, stressing the importance of comprehensive safety profiles for any permanent modification via gene therapy.

The treatment from Verve Therapeutics (now under Eli Lilly) targets LDL cholesterol by silencing the PCSK9 gene. The delivered machinery—a CRISPR-like tool encased in lipid nanoparticles—precisely edits liver cell DNA, preventing the synthesis of PCSK9. This allows the liver to clear more LDL from the bloodstream. The study’s upbeat outlook from lead author Dr. Sekar Kathiresan, whose personal family history of heart disease fueled the project, highlights its potential.

The therapy’s affordability remains a critical question, considering current gene therapies can cost millions. Eli Lilly’s Dr. Daniel Skovronsky emphasized the goal: “We’re aiming for a treatment that could one day be part of primary care.” Meanwhile, existing treatments—such as daily statins or PCSK9-inhibiting injections—remain underutilized, with nearly half of high-risk patients discontinuing medication. For patients like Kristy Faulkner, who stopped cholesterol drugs after a heart attack, a one-time solution could eliminate dependency on lifelong medications.

Another patient, Alice Thomas, 64, found herself ineligible for affordable statins due to financial constraints and insurance denials. After joining the trial, her LDL levels plummeted from 190 to 50 within two weeks. “This is life-saving,” she said, “One shot and it’s over.” Dr. Erica Spatz of Yale, advocating for broader access, called the treatment a “breakthrough” for non-adherent patients.

While hundreds of participants await enrollment in the expanded trial, researchers stress the study’s early stage. Detailed safety data—and regulatory approval—remain years away. Yet the promise of a single infusion curing a chronic condition has sparked optimism, with experts envisioning a future where such therapies become routine in heart disease prevention.

Source link